These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 788892)

  • 1. A comparative study of the antitumor effectiveness of E. coli and Erwinia asparaginases.
    Roberts J; Schmid FA; Old LJ; Stockert E
    Cancer Biochem Biophys; 1976 May; 1(4):175-8. PubMed ID: 788892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in the therapeutic, immunological, and clearance properties of Escherichia coli and Erwinia carotovora L-asparaginases by attachment of poly-DL-alanyl peptides.
    Uren JR; Ragin RC
    Cancer Res; 1979 Jun; 39(6 Pt 1):1927-33. PubMed ID: 376113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
    Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of immunization to L-asparaginase on antitumor and enzymatic activity.
    Goldberg AI; Cooney DA; Glynn JP; Homan ER; Gaston MR; Milman HA
    Cancer Res; 1973 Feb; 33(2):256-61. PubMed ID: 4569788
    [No Abstract]   [Full Text] [Related]  

  • 5. [Results of an experimental study of the antitumor activity of 1-asparaginase from E. coli and Erw. carotovora].
    Terent'eva TG; Sokolov AB; Navashin SM
    Antibiotiki; 1977 Jan; 22(1):78-81. PubMed ID: 320935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic analysis of hepatotoxicity associated with antineoplastic asparaginases.
    Durden DL; Salazar AM; Distasio JA
    Cancer Res; 1983 Apr; 43(4):1602-5. PubMed ID: 6339039
    [No Abstract]   [Full Text] [Related]  

  • 7. Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli.
    Ohnuma T; Holland JF; Meyer P
    Cancer; 1972 Aug; 30(2):376-81. PubMed ID: 4559405
    [No Abstract]   [Full Text] [Related]  

  • 8. [Bacterial L-asparaginase and glutamin(asparagin)ase: some properties, structure and anti-tumor activity].
    Sokolov NN; Zanin VA; Aleksandrova SS
    Vopr Med Khim; 2000; 46(6):531-48. PubMed ID: 11234278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the L-asparaginases from Escherichia coli and Erwinia carotovora as immunosuppressants.
    Ashworth LA; MacLennan AP
    Cancer Res; 1974 Jun; 34(6):1353-9. PubMed ID: 4596965
    [No Abstract]   [Full Text] [Related]  

  • 10. Asparaginase: molecular and enzymic requirements for use as an antileukaemia agent.
    Wade HE
    J Gen Microbiol; 1971 Mar; 65(3):x-xi. PubMed ID: 4997395
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system.
    Albertsen BK; Schrøder H; Ingerslev J; Jakobsen P; Avramis VI; Müller HJ; Carlsen NT; Schmiegelow K
    Br J Haematol; 2001 Dec; 115(4):983-90. PubMed ID: 11843837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relationship between the magnitude of Km and pH for L-asparaginase].
    Libinson GS; Mikhalev AV
    Biokhimiia; 1976 Jan; 41(1):149-52. PubMed ID: 6070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia.
    Asselin BL
    Adv Exp Med Biol; 1999; 457():621-9. PubMed ID: 10500842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxic and immunodepressive effects of L-asparaginase from E. coli and from Erwinia carotovora following chronic administration in rats.
    Celle G; Dodero M; Cuneo P; Picciotto A; Brambilla G; Cavanna M; Pannaciulli I
    Arzneimittelforschung; 1977; 27(11):2046-50. PubMed ID: 341899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.
    Duval M; Suciu S; Ferster A; Rialland X; Nelken B; Lutz P; Benoit Y; Robert A; Manel AM; Vilmer E; Otten J; Philippe N
    Blood; 2002 Apr; 99(8):2734-9. PubMed ID: 11929760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Purification of microbial asparaginases by the aid of affinity chromatography].
    Mardashev SR; Nikolaev AIa; Kozlov EA; Petriĭ OP
    Biokhimiia; 1975; 40(1):78-82. PubMed ID: 1095078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
    Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
    Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antigenic properties of 1-asparaginases isolated from different species and strains of bacteria].
    Chaĭkovskaia SM; Makarova RA; Tochenaia NP; Frolova MA
    Antibiotiki; 1976 Mar; 21(3):255-8. PubMed ID: 776078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gel entrapped L-asparaginase: kinetic behavior and antitumor activity.
    O'Driscoll KF; Korus RA; Ohnuma T; Walczack IM
    J Pharmacol Exp Ther; 1975 Nov; 195(2):382-8. PubMed ID: 241845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
    Boos J
    Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.